NIKKEI 225
28,804.85 +96.25 (+0.34%) HANG SENG
26,126.93 +109.43 (+0.42%) CRUDE OIL
84.05 +0.29 (+0.35%) GOLD FUTURES
1,794.10 -2.20 (-0.12%) DOW
35,677.02 +73.92 (+0.21%) BTC-GBP
44,236.75 -470.37 (-1.05%)
CureVac N.V. (CVAC)
After hours: 07:57PM EDT
| Previous close | 40.18 |
| Open | 39.45 |
| Bid | 38.25 x 3200 |
| Ask | 38.65 x 900 |
| Day's range | 38.25 - 39.64 |
| 52-week range | 37.54 - 151.80 |
| Volume | 456,955 |
| Avg. volume | 686,715 |
| Market cap | 7.208B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.14 |
| Earnings date | 16 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 69.61 |
- PA Media: Money
CureVac ditches first generation Covid vaccine to focus efforts on variant jab
The announcement will not affect UK vaccine supply.
- Motley Fool
Why CureVac Stock Is Tumbling Today
What happened Shares of CureVac (NASDAQ: CVAC) were tumbling 7.4% as of 11 a.m. EDT on Tuesday after falling as much as 13% earlier in the morning. The decline came after the company announced it's withdrawing COVID-19 vaccine candidate CVnCoV from the European Medicines Agency's approval process.
- EQS Group
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
DGAP-News: CureVac / Key word(s): Strategic Company Decision12.10.2021 / 13:02 The issuer is solely responsible for the content of this announcement.CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology- COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK- First-generation vaccine candidate, CVnCoV, to be withdrawn from regulatory review due to potential overlap with approval timeli
